[go: up one dir, main page]

SG11202106483WA - Antibodies that neutralize hepatitis b virus and uses thereof - Google Patents

Antibodies that neutralize hepatitis b virus and uses thereof

Info

Publication number
SG11202106483WA
SG11202106483WA SG11202106483WA SG11202106483WA SG11202106483WA SG 11202106483W A SG11202106483W A SG 11202106483WA SG 11202106483W A SG11202106483W A SG 11202106483WA SG 11202106483W A SG11202106483W A SG 11202106483WA SG 11202106483W A SG11202106483W A SG 11202106483WA
Authority
SG
Singapore
Prior art keywords
antibodies
virus
neutralize hepatitis
neutralize
hepatitis
Prior art date
Application number
SG11202106483WA
Inventor
Davide Corti
Original Assignee
Humabs Biomed Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Humabs Biomed Sa filed Critical Humabs Biomed Sa
Publication of SG11202106483WA publication Critical patent/SG11202106483WA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/082—Hepadnaviridae, e.g. hepatitis B virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/02—Hepadnaviridae, e.g. hepatitis B virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/26—Infectious diseases, e.g. generalised sepsis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
SG11202106483WA 2018-12-19 2019-12-18 Antibodies that neutralize hepatitis b virus and uses thereof SG11202106483WA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862782274P 2018-12-19 2018-12-19
US201962860085P 2019-06-11 2019-06-11
PCT/US2019/067216 WO2020132091A2 (en) 2018-12-19 2019-12-18 Antibodies that neutralize hepatitis b virus and uses thereof

Publications (1)

Publication Number Publication Date
SG11202106483WA true SG11202106483WA (en) 2021-07-29

Family

ID=69182688

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202106483WA SG11202106483WA (en) 2018-12-19 2019-12-18 Antibodies that neutralize hepatitis b virus and uses thereof

Country Status (24)

Country Link
US (1) US12304946B2 (en)
EP (2) EP3898668B1 (en)
JP (1) JP7498714B2 (en)
KR (1) KR20210126558A (en)
CN (2) CN118108836A (en)
AU (1) AU2019403245B2 (en)
BR (1) BR112021012094A2 (en)
CA (1) CA3121004A1 (en)
DK (1) DK3898668T5 (en)
ES (1) ES2961791T3 (en)
FI (1) FI3898668T3 (en)
HR (1) HRP20231440T1 (en)
HU (1) HUE063732T2 (en)
IL (1) IL284044A (en)
LT (1) LT3898668T (en)
MX (1) MX2021006756A (en)
PH (1) PH12021551458A1 (en)
PL (1) PL3898668T3 (en)
PT (1) PT3898668T (en)
SG (1) SG11202106483WA (en)
SI (1) SI3898668T1 (en)
TW (1) TW202039547A (en)
WO (1) WO2020132091A2 (en)
ZA (1) ZA202104213B (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12304946B2 (en) 2018-12-19 2025-05-20 Humabs Biomed Sa Antibodies that neutralize hepatitis B virus and uses thereof
BR112022003698A2 (en) * 2019-08-29 2022-05-24 Vir Biotechnology Inc Method of treating a hepatitis b virus infection and pharmaceutical composition
PH12022553569A1 (en) 2020-06-24 2023-04-12 Humabs Biomed Sa Engineered hepatitis b virus neutralizing antibodies and uses thereof
TW202229350A (en) 2020-10-14 2022-08-01 美商維里迪恩醫療股份有限公司 Compositions and methods for treatment of thyroid eye disease
EP4284428A1 (en) * 2021-01-26 2023-12-06 VIR Biotechnology, Inc. Compositions and methods for treating hepatitis b virus infection
CN118139877A (en) * 2021-10-18 2024-06-04 高丽大学校产学协力团 Fc variants with increased pH-dependent FcRn binding and FcγRIIIa binding selectivity
JP2025518543A (en) * 2022-05-19 2025-06-17 ヴィア・バイオテクノロジー・インコーポレイテッド Compositions and methods for treating hepatitis D virus (HDV) infection and related diseases - Patents.com
CN119403827A (en) * 2022-05-19 2025-02-07 维尔生物科技公司 Compositions and methods for treating hepatitis B virus (HBV) infection and HBV-related diseases
AR129399A1 (en) 2022-05-23 2024-08-21 Vir Biotechnology Inc DESIGNED ANTIBODIES NEUTRALIZING HEPATITIS B VIRUS AND THEIR USES
WO2024148263A1 (en) * 2023-01-06 2024-07-11 Victorian Infectious Diseases Reference Laboratory Methods and compositions for antibody treatment of hepatitis b infection

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (en) 1971-02-10 1977-09-15 Organon Nv METHOD FOR THE DETERMINATION AND DETERMINATION OF SPECIFIC BINDING PROTEINS AND THEIR CORRESPONDING BINDABLE SUBSTANCES.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3766162A (en) 1971-08-24 1973-10-16 Hoffmann La Roche Barbituric acid antigens and antibodies specific therefor
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4233402A (en) 1978-04-05 1980-11-11 Syva Company Reagents and method employing channeling
JPS5896026A (en) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd Novel urokinase derivative, its preparation and thrombolytic agent containing the same
EP0098110B1 (en) 1982-06-24 1989-10-18 NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JAPAN CHEMICAL RESEARCH CO., LTD Long-acting composition
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4831175A (en) 1986-09-05 1989-05-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
EP0861893A3 (en) 1991-09-19 1999-11-10 Genentech, Inc. High level expression of immunoglobulin polypeptides
US5595721A (en) 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
EP0906337A2 (en) 1996-04-18 1999-04-07 Abbott Laboratories AN ANTIGENIC EPITOPE OF THE u A /u DETERMINANT OF HEPATITIS B SURFACE ANTIGEN AND USES THEREOF
GB9608626D0 (en) 1996-04-25 1996-07-03 Univ College Of London Hepatitis b monoclonal antibodies
WO1998029442A1 (en) 1996-12-30 1998-07-09 Innogenetics N.V. ANNEXIN V-BINDING POLYPEPTIDES DERIVED FROM HBsAg AND THEIR USES
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
EP1097172A1 (en) * 1998-07-21 2001-05-09 Genmab A/S Anti hepatitis c virus antibody and uses thereof
US20020102208A1 (en) 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
MY133346A (en) 1999-03-01 2007-11-30 Biogen Inc Kit for radiolabeling ligands with yttrium-90
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
ES2248127T3 (en) 1999-10-04 2006-03-16 Medicago Inc. METHOD FOR REGULATING THE TRANSCRIPTION OF FOREIGN GENES IN THE PRESENCE OF NIGTROGEN.
EP1597280B2 (en) 2003-02-26 2016-08-24 Institute for Research in Biomedicine Monoclonal antibody production by ebv transformation of b cells
EP1641827A2 (en) 2003-06-27 2006-04-05 Biogen Idec MA Inc. Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions
US8802820B2 (en) * 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
WO2006076640A1 (en) 2005-01-14 2006-07-20 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Monoclonal antibodies that bind or neutralize hepatitis b virus
AU2008254951A1 (en) 2007-05-14 2008-11-27 Biogen Idec Ma Inc. Single-chain Fc (ScFc) regions, binding polypeptides comprising same, and methods related thereto
KR20090056537A (en) 2007-11-30 2009-06-03 주식회사 녹십자 Composition for the prevention or treatment of hepatitis V virus infection comprising as an active ingredient an antibody having hepatitis V virus neutralizing ability
WO2010046775A2 (en) 2008-10-22 2010-04-29 Institute For Research In Biomedicine Methods for producing antibodies from plasma cells
EP2210903A1 (en) 2009-01-21 2010-07-28 Monoclonal Antibodies Therapeutics Anti-CD160 monoclonal antibodies and uses thereof
EP3683317A3 (en) 2009-05-13 2020-09-30 Genzyme Corporation Anti-human cd52 immunoglobulins
EP2756094B1 (en) 2011-08-15 2017-12-27 Medlmmune, LLC Anti-b7-h4 antibodies and their uses
CN104487090B (en) 2012-07-10 2017-06-16 株式会社绿十字 A kind of antibody compositions hepatitis b virus infected for preventing or treating saltant type
SG11201501255PA (en) 2012-08-30 2015-03-30 Replicor Inc Methods for the treatment of hepatitis b and hepatitis d infections
GB201216649D0 (en) 2012-09-18 2012-10-31 Univ Birmingham Agents and methods
CN104955837A (en) 2012-11-12 2015-09-30 海德堡吕布莱希特-卡尔斯大学 Development of HBV- and/or HDV-susceptible cells, cell lines and non-human animals
SG11201504764SA (en) 2012-12-19 2015-07-30 Amplimmune Inc Anti-human b7-h4 antibodies and their uses
US20140294812A1 (en) 2013-03-15 2014-10-02 Xencor, Inc. Fc variants that improve fcrn binding and/or increase antibody half-life
US10167333B2 (en) 2014-01-16 2019-01-01 Mario Umberto Francesco Mondelli Neutralizing human monoclonal antibodies against hepatitis B virus surface antigen
TWI681969B (en) 2014-01-23 2020-01-11 美商再生元醫藥公司 Human antibodies to pd-1
AR101848A1 (en) 2014-09-12 2017-01-18 Genentech Inc ANTI-B7-H4 AND IMMUNOCATE PLAYERS
MX2017004311A (en) 2014-10-03 2017-12-07 Dana Farber Cancer Inst Inc Glucocorticoid-induced tumor necrosis factor receptor (gitr) antibodies and methods of use thereof.
EP3295951B1 (en) 2015-02-19 2020-04-22 Compugen Ltd. Anti-pvrig antibodies and methods of use
US10301377B2 (en) 2015-02-24 2019-05-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Middle east respiratory syndrome coronavirus immunogens, antibodies, and their use
JO3620B1 (en) 2015-08-05 2020-08-27 Amgen Res Munich Gmbh Immunological check point inhibitors for use in the treatment of blood-borne cancers
WO2017059878A1 (en) * 2015-10-07 2017-04-13 Humabs Biomed Sa Antibodies that potently neutralize hepatitis b virus and uses thereof
MY186414A (en) 2015-12-15 2021-07-22 Gilead Sciences Inc Human immunodeficiency virus neutralizing antibodies
US20200157192A1 (en) 2017-05-10 2020-05-21 Albajuna Therapeutics, S.L. Fc-fusion protein derivatives with high dual hiv antiviral and immunomodulatory activity
JP2021507704A (en) 2017-12-19 2021-02-25 ザ ロックフェラー ユニバーシティー Fc region variant of human IgG with improved effector function
US12304946B2 (en) 2018-12-19 2025-05-20 Humabs Biomed Sa Antibodies that neutralize hepatitis B virus and uses thereof
MX2021006954A (en) 2018-12-20 2021-10-22 Vir Biotechnology Inc Combination hbv therapy.
BR112022003698A2 (en) 2019-08-29 2022-05-24 Vir Biotechnology Inc Method of treating a hepatitis b virus infection and pharmaceutical composition

Also Published As

Publication number Publication date
EP4292659A2 (en) 2023-12-20
BR112021012094A2 (en) 2021-08-31
ZA202104213B (en) 2023-12-20
ES2961791T3 (en) 2024-03-13
TW202039547A (en) 2020-11-01
AU2019403245B2 (en) 2024-10-31
EP3898668A2 (en) 2021-10-27
HUE063732T2 (en) 2024-01-28
DK3898668T3 (en) 2023-11-13
WO2020132091A9 (en) 2021-02-25
SI3898668T1 (en) 2024-02-29
FI3898668T3 (en) 2023-11-28
PL3898668T3 (en) 2024-04-02
US20220127336A1 (en) 2022-04-28
WO2020132091A3 (en) 2020-10-15
DK3898668T5 (en) 2024-08-05
LT3898668T (en) 2023-11-10
AU2019403245A1 (en) 2021-07-22
CN113544148B (en) 2024-04-05
CN113544148A (en) 2021-10-22
WO2020132091A2 (en) 2020-06-25
MX2021006756A (en) 2021-09-28
IL284044A (en) 2021-08-31
PT3898668T (en) 2023-12-06
PH12021551458A1 (en) 2022-05-02
EP4292659A3 (en) 2024-03-20
US12304946B2 (en) 2025-05-20
EP3898668B1 (en) 2023-08-30
HRP20231440T1 (en) 2024-03-01
KR20210126558A (en) 2021-10-20
JP2022514940A (en) 2022-02-16
CA3121004A1 (en) 2020-06-25
JP7498714B2 (en) 2024-06-12
CN118108836A (en) 2024-05-31

Similar Documents

Publication Publication Date Title
IL284044A (en) Antibodies that neutralize hepatitis b virus and uses thereof
IL258326B (en) Antibodies that potently neutralize hepatitis b virus and uses thereof
ZA202004827B (en) Anti-cd73 antibodies and uses thereof
IL282968A (en) Anti-nkg2a antibodies and uses thereof
SG11202105885WA (en) Anti-claudin antibodies and uses thereof
IL275826A (en) Anti-mct1 antibodies and uses thereof
SG11202009772PA (en) Anti-dll3 antibodies and uses thereof
IL281297A (en) Anti-npr1 antibodies and uses thereof
SG11202102335YA (en) Anti-tnfrsf9 antibodies and uses thereof
SG11202009625WA (en) Anti-trem-1 antibodies and uses thereof
IL280321A (en) Anti-cxcr2 antibodies and uses thereof
IL277075A (en) Anti-phf-tau antibodies and uses thereof
SG10201905229VA (en) Anti-Dengue Virus Antibodies and Applications Thereof
IL283875A (en) Anti-il-27 antibodies and uses thereof
IL277330A (en) Anti-il-27 antibodies and uses thereof
KR101882087B1 (en) Monoclonal antibody against viral hemorrhagic septisemia virus and use thereof
SG11202012680TA (en) Anti-l1cam antibodies and uses thereof
IL283926A (en) Anti-alpha-synuclein antibodies and uses thereof
IL276548A (en) Bcma-binding antibodies and uses thereof
SG11202103849TA (en) Anti-periostin antibodies and uses thereof
HK40056051B (en) Antibodies that neutralize hepatitis b virus and uses thereof
HK40061690A (en) Antibodies that neutralize hepatitis b virus and uses thereof
HK40074418B (en) Antibodies that neutralize hepatitis b virus and uses thereof
ZA202104076B (en) Hepatitis b virus vaccine and uses thereof
GB201808500D0 (en) Virus and virus use